Long-term follow-up of survivors of childhood cancer (SIGN Clinical Guideline 132)

Hoong-Wei Gan,1,2 Helen A Spoudeas2,3

BACKGROUND

Five-year childhood cancer survival rates have increased to 80–90% for some tumours due to intensified treatments and better supportive care imposed on an incidence stable over four decades.1,2 Between 2005 and 2012, the number of UK survivors has risen from 26 000 to 33 000, or from 1:1000 to 1:715 UK adults.3,4 However, 40% experience chronic severe or life-threatening consequences (‘late effects’) of their tumour and/or its treatment.5 The recent National Cancer Survivorship Initiative (NCSI) has highlighted the unmet need in service provision for adult childhood cancer survivors, with a proposed survivorship framework and stratified care pathways modelled on >20 years’ prior experience.6,7 In March 2013, the Scottish Intercollegiate Guidelines Network (SIGN) published updated guidance on long-term follow-up of childhood cancer survivors to aid the ‘identification, assessment and management of late effects’ aimed at primary, secondary and tertiary healthcare practitioners.8 The Guideline Development Group (GDG) included representatives from paediatric haematology, oncology, endocrinology, reproductive medicine, cardiology, general paediatrics and general practice, as well as a survivor.

PREVIOUS AND OTHER ASSOCIATED GUIDELINES

The previous SIGN 76 guideline was published in 2004. This revision updates information on fertility preservation, cardiac late effects and patient information provision, and provides new sections on subsequent primary cancers (SPCs), bone health and metabolic syndrome. The UK Children’s Cancer Study Group’s (UK CCSG) best practice statement3 is a potentially valuable companion guideline for tertiary care practitioners requiring details of therapeutic regimens and their toxicity profiles to individualise care for those most affected.

KEY ISSUES

▸ Section 11: long-term follow-up provides a useful summary of the recommendations. It recognises the multisystemic and evolving nature of late effects over decades of survival, concluding a need for lifelong multidisciplinary follow-up (table 1). The authors suggest a three-tiered follow-up stratified by disease-related and/or treatment-related morbidity risk (table 2) and list the key multidisciplinary professionals required (box 1).

▸ Subsequent primary cancers (SPCs)—The British Childhood Cancer Survivor Study10 and others have shown an excess SPC risk—>50% due to gastrointestinal, genitourinary, breast and lung cancers—persisting into old age.

▸ Fertility—The impact of cancer treatment on the pituitary–gonadal axis, reproductive capacity and options for pretreatment fertility preservation are complex and differ between the sexes (see British Fertility Society review for a fuller discussion11). In boys, post-treatment sub/infertility may exist despite a normal puberty and potency.12 With intracytoplasmic sperm injection, oligospermia is no barrier to fertility preservation, while long-term spermatogenic recovery is possible.13 By contrast, pubertal delay or secondary amenorrhoea may herald sub/infertility in girls whose options are more limited. Pretreatment gonadotropin-releasing hormone analogues, ovarian transposition and oocyte collection are unproven and/or impracticable. Prepubertal children of either sex have no recommended options outside a clinical trial. Miscarriage rates are increased, but
<table>
<thead>
<tr>
<th>Late effect</th>
<th>High-risk factors</th>
<th>Specific late effects</th>
<th>Screening methods/ management</th>
<th>Evidence level/grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsequent primary cancers (SPCs)</td>
<td>Genetic predisposition, eg, NF-1 Radiotherapy</td>
<td>Delayed presentation &gt;5 years from treatment, at edge of radiation field (eg, mediastinal radiotherapy and breast SPCs)</td>
<td>As per guidance for specific syndromes No consensus Promote healthy lifestyle behaviours</td>
<td>3/C</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy* (alkylating agents, epipodophyllotoxins)</td>
<td>Increased risk of all SPCs</td>
<td>No consensus Promote healthy lifestyle behaviours</td>
<td>3/C</td>
</tr>
<tr>
<td>Sub-/infertility</td>
<td>Both sexes Cranial radiotherapy</td>
<td>Hypogonadotropic hypogonadism (pubertal arrest/ delay)</td>
<td>See individual sections for assessment depending on sex</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Pelvic radiotherapy Boys</td>
<td>Sexual dysfunction</td>
<td>Consider psychological referral</td>
<td>3–4/D</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy* (alkylating agents)</td>
<td>Azoospermia</td>
<td>Semen analysis+cryopreservation, FSH, inhibin B</td>
<td>3/D</td>
</tr>
<tr>
<td></td>
<td>Gonadal radiotherapy/ total body irradiation (TBI)</td>
<td>Azoospermia</td>
<td>Semen analysis+cryopreservation, FSH, inhibin B</td>
<td>3/D</td>
</tr>
<tr>
<td></td>
<td>Girls</td>
<td>Hypergonadotropic hypogonadism (pubertal arrest/ delay/ oligoamenorrhoea)</td>
<td>Regular pubertal assessment, LH, testosterone +pubertal induction/ testosterone supplementation</td>
<td>3/D</td>
</tr>
<tr>
<td>Cardiac effects</td>
<td>Chemotherapy (anthracyclines)</td>
<td>Congestive heart failure</td>
<td>Echocardiography: Fractional shortening (FS) and ejection fraction (EF) measurements</td>
<td>3–4/D</td>
</tr>
<tr>
<td></td>
<td>Cardiac/mediastinal radiotherapy</td>
<td>Cardiovascular (especially coronary artery) disease</td>
<td>2–3 yearly if anthracycline dose &gt;250 mg/m² 5 yearly if anthracycline dose &lt;250 mg/m² Treat as per regular heart failure/cardiovascular disease guidelines Promote healthy lifestyle behaviours</td>
<td>3/D</td>
</tr>
<tr>
<td>Bone health</td>
<td>Chemotherapy (glucocorticoids, high dose methotrexate, 6-mercaptopturine) Cranial radiotherapy Bone marrow transplantation Endocrine dysfunction (GH deficiency, hypogonadism, hypothyroidism)</td>
<td>Osteoporosis (osteonecrosis with glucocorticoids)</td>
<td>Dual energy X-ray absorptometry (DXA)/ peripheral quantitative CT/ quantitative ultrasound: BMD or bone mineral content (BMC) Z-scores adjusted for age, sex and height 2 years post-end of treatment Serial measurements not required unless abnormal or clinical change Sex steroid replacement Promote healthy lifestyle behaviours</td>
<td>3/D</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>ALL (especially after bone marrow transplantation) Brain tumours (especially after cranial radiotherapy and growth hormone deficiency)</td>
<td>Obesity Dyslipidaemia Insulin resistance Cardiovascular disease</td>
<td>BP and BMI: Annually in all survivors Fasting glucose, insulin, lipid profile: 2 yearly if obese/ overweight 5-yearly if normal weight Treat as per regular obesity guidelines</td>
<td>3–4/D</td>
</tr>
<tr>
<td>Cognitive outcomes</td>
<td>Cranial radiotherapy</td>
<td>Cognitive decline Psychosocial dysfunction</td>
<td>Neuropsychological assessment: Pretreatment and then annually</td>
<td>3/D</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>Late effect</th>
<th>High-risk factors</th>
<th>Specific late effects</th>
<th>Screening methods/ management</th>
<th>Evidence level/grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth</td>
<td>Craniopharyngiomas (and other hypothalamic/pituitary tumours)</td>
<td>Growth hormone deficiency</td>
<td>Regular height monitoring</td>
<td>2+/B/C</td>
</tr>
<tr>
<td></td>
<td>Cranial radiotherapy</td>
<td>Pubetal delay/ arrest</td>
<td>Regular height monitoring + sitting height</td>
<td>2+/B/C</td>
</tr>
<tr>
<td></td>
<td>(Cranio) spinal radiotherapy</td>
<td>Growth hormone deficiency</td>
<td>Paediatric endocrinology referral if reduced height velocity</td>
<td>2+/2++/B-C</td>
</tr>
<tr>
<td>Thyroid dysfunction</td>
<td>Neck, (crani) spinal and total body irradiation</td>
<td>Primary hypothyroidism</td>
<td>Thyroid function tests: At end of treatment and then annually</td>
<td>2+/B</td>
</tr>
<tr>
<td></td>
<td>MIBG therapy</td>
<td>Thyroid nodules</td>
<td>Thyroid hormone replacement</td>
<td>2+2+/+D</td>
</tr>
<tr>
<td></td>
<td>Cranial radiotherapy</td>
<td>Thyroid cancer</td>
<td>No consensus about thyroid nodules/ cancer—patient education</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chemotherapy</td>
<td>Second-tertiary hypothyroid</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Clinicians should note that all chemotherapy may be associated with an increased risk of SPCs and sub-fertility.

ALL, acute lymphoblastic leukaemia; AMH, anti-Mullerian hormone; BMD, bone mineral density; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinising hormone; MIBG, metaiodobenzylguanidine; NF-1, neurofibromatosis type 1; SIGN, Scottish Intercollegiate Guidelines Network.

**Underlying Evidence Base**

These SIGN guidelines represent a synthesis of systematic reviews summarising the best available evidence in accordance with standardised methodology. Unlike the National Institute for Health and Care Excellence (NICE), SIGN does not require a mandatory cost-effectiveness analysis. Unlike the National Institute for Health and Care Excellence (NICE), SIGN does not require a mandatory cost-effectiveness analysis.
Table 2  Suggested risk stratification of levels of follow-up for 5-year childhood cancer survivors after completion of treatment (reproduced from SIGN 132: Long term follow up of survivors of childhood cancer by kind permission)8

<table>
<thead>
<tr>
<th>Level</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Frequency</th>
<th>Examples</th>
</tr>
</thead>
</table>
| 1     | Surgery alone Low-risk chemotherapy | Postal/telephone | 1–2 yearly | Survivors of Wilms’ tumour stage 
I/II Langerhans cell histiocytosis (single system disease) 
Germ cell tumours (surgery only) |
| 2     | Chemotherapy Cranial radiotherapy ≤24 Gy | Nurse/primary care-led | 1–2 yearly | Majority of survivors |
| 3     | Any other radiotherapy (cranial radiotherapy >24 Gy) Megatherapy (ie, high-dose chemotherapy) | Medically supervised dedicated long-term follow-up clinic | Annually | Survivors of Any brain tumour Bone marrow transplantation Stage 4 patients of any tumour type |

SIGN, Scottish Intercollegiate Guidelines Network.

Hierarchy of evidence from level 1 (meta-analyses, systematic reviews or randomised controlled trials) to level 4 (expert opinion).

**HOW DO I IMPLEMENT THESE GUIDELINES IN MY PRACTICE?**

- Primary care practitioners need to be alert to the many late organ toxicities incurred by increasing treatment intensity that may manifest decades after treatment. Lifelong surveillance for endocrinopathies, subfertility, SPCs, cardiovascular disease, obesity and metabolic syndrome particularly in low-risk patients can only realistically occur in primary care, alongside supporting healthy lifestyle behaviours (including monitoring vitamin D status) and participation in secondary/tertiary follow-up. Young adult survivors may seek support for psychological illness or subfertility.

- Secondary care practitioners will monitor growth, puberty, thyroid function and neurocognitive development until adulthood, with appropriate specialist referral. Letters of support may be required for missed school attendances, statementing and disability living allowance applications. Adult physicians will be responsible for lifelong monitoring of cardiovascular disease, obesity, thyroid function, bone and sexual health, fertility and SPCs.

- Tertiary care practitioners should see all those at highest risk (brain, pelvic, bone tumour and transplant survivors) for hypothalamic-pituitary hormone dysfunction, fertility counselling, cardiac and cognitive assessments and psychological support. Clear end-of-treatment summaries with information regarding long-term surveillance needs and likely consequences are required. Implicit in the latter are the increased resources needed for such age-appropriate tertiary assessment and rehabilitation services.

**CONTROVERSIES AND UNADDRESSED ISSUES**

The level of care provided to childhood cancer survivors remains highly variable across the UK,19 and controlled trials on the optimum frequency, duration and

**Clinical bottom line**

- Childhood cancer survivors require lifelong monitoring to limit late consequences of their tumour and/or treatment, but the optimum service delivery model remains incompletely defined.
- While risk factors associated with certain late effects are known, many evolve over decades, with data interpretation confounded by retrospective and cross-sectional study designs.
- Tertiary centres are developing one-stop age-appropriate multidisciplinary services for those at highest risk, but the majority will remain in primary and secondary care.
- All practitioners must thus be aware of consequences of cancer cure and thresholds for referral. In this respect, the SIGN guidance provides a helpful way forward for much needed service development and summarises the current evidence base.
- More prospective long-term morbidity outcome studies are required from current interventional trials to define the balance between improving survival with increasing treatment intensity and the quality of survivorship.
quality of follow-up are still needed to determine the effectiveness of secondary prevention of, for example, congestive cardiac failure or hypocortisolaemic

**Box 2 Critical review**

- Timely update limited by absence of high-quality evidence for the cost effectiveness of the recommended lifelong three-tiered follow-up framework. Evidence graded mainly C–D (none above B) consisting largely of uncontrolled qualitative studies of patient/family satisfaction, not morbidity or mortality.21
- Inherent bias in Guideline Development Group (GDG) composition—no renal, respiratory or neurology/neuropsychology representatives with consequent omissions of important treatment-related renal, neurological and pulmonary toxicities (detailed in the UK CCSG Best Practice Statement).
- The Human Fertilisation and Embryology Act (2008)22 governing storage and use of haploid gametes and embryos is not mentioned. It mandates personal (not proxy) consent, even in children; hence an intellectual (‘Gillick’) competency assessment is required. Blood-borne virus (HIV, hepatitis B & C) testing prior to storage and written consent regarding use after death is also necessary.
- The endocrine and cognitive outcomes sections have not been updated (cited references are over 15 years old). As a result:
  - The cited data on pituitary craniopharyngiomas and hypothalamic obesity have been superseded by prospective outcome studies,23 retrospective reviews24 and guidelines,25 not identified by the GDG search strategy.
  - The recommendation that all cranially irradiated patients receive annual cognitive assessments has never been achieved even in the context of a prospective trial.15
  - The perception that cranial irradiation per se causes eventual life-threatening pituitary deficits (eg, adrenocorticotropic hormone deficiency deficiency) persists from 1987 data on adult pituitary tumours; newer evidence suggests pituitary dysfunction is confined to GH deficiency and precarious puberty except in the presence of a suprasellar tumour, which is most likely causative.26
  - Given the risk of radiation-associated subsequent primary cancers (1% lifetime risk of thyroid cancer), the carcinogenicity of nuclear fallout and an elevated thyroid-stimulating hormone (TSH)27 and the long-term cardiovascular mortality risk of subclinical hypothyroidism,28 few clinicians would overlook screening for and treating compensated hypothyroidism (raised TSH, normal free T4) after neck irradiation.

**FURTHER RESOURCES**

- National Cancer Survivorship Initiative (NCSI) website http://www.ncsi.org.uk/
- Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer (PanCare) http://www.pancare.eu/en/

**Acknowledgements** We would like to thank SIGN for their kind permission in the use of table 2 and box 1 for this review.

**Contributors** H-WG wrote the initial manuscript draft, and HAS provided significant editions and useful expert opinion.

**Competing interests** None.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**


20 Hjorth L, Kvarnstrom E. Pancare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies. 2013. [cited 2013 2 December 2013]; http://www.pancaresurup.eu


